Genomma Lab InternacionalB de CV (MEX:LABB) ROCE %: 19.51% (As of Mar. 2026)


MEX:LABB Genomma Lab Internacional SAB de CV MEX:LABB
66 GF Score
Price MXN15.04
GF Value MXN17.64
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Genomma Lab InternacionalB de CV ROCE %?

Genomma Lab InternacionalB de CV MEX:LABB +2.59% 66 ROCE % is 19.51% as of Mar. 2026. GuruFocus rates MEX:LABB with a GF Score™ of 66/100 and a GF Value™ of MXN17.64 (Modestly Undervalued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Genomma Lab InternacionalB de CV's annualized ROCE % for the quarter that ended in Mar. 2026 was 19.51%.

Genomma Lab InternacionalB de CV  (MEX:LABB) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Genomma Lab InternacionalB de CV ROCE % Related Terms

Genomma Lab InternacionalB de CV ROCE % Historical Data

* Premium members only.

The historical data trend for Genomma Lab InternacionalB de CV's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genomma Lab InternacionalB de CV ROCE % Chart

Genomma Lab InternacionalB de CV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.96 20.28 19.39 24.75 19.56

Genomma Lab InternacionalB de CV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.91 18.39 19.02 18.30 19.51
MEX:LABB
66GF Score
Genomma Lab Internacional SAB de CV MEX:LABB
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genomma Lab InternacionalB de CV ROCE % Calculation

Genomma Lab InternacionalB de CV's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=3230.448/( ( (23017.803 - 6538.418) + (23690.512 - 7145.479) )/ 2 )
=3230.448/( (16479.385+16545.033)/ 2 )
=3230.448/16512.209
=19.56 %

Genomma Lab InternacionalB de CV's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=3287.58/( ( (23690.512 - 7145.479) + (24800.496 - 7652.101) )/ 2 )
=3287.58/( ( 16545.033 + 17148.395 )/ 2 )
=3287.58/16846.714
=19.51 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 19.51% mean?
Genomma Lab InternacionalB de CV (MEX:LABB) has a ROCE % of 19.51% as of Mar. 2026.
Is Genomma Lab InternacionalB de CV's ROCE % too high?
Genomma Lab InternacionalB de CV's current ROCE % is 19.51%. The Drug Manufacturers industry median ROCE % is 7.00. Genomma Lab InternacionalB de CV's value of 19.51% is 178.9% above this industry median. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's ROCE % compare to ZTS and UTHR?
Genomma Lab InternacionalB de CV's ROCE % of 19.51% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. Genomma Lab InternacionalB de CV's value of 19.51% is 178.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genomma Lab InternacionalB de CV's current ROCE % of 19.51% is 178.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomma Lab InternacionalB de CV's current ROCE % is 19.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (MEX:LABB) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN17.64, compared to a current price of MXN15.04 — trading 14.7% below its estimated fair value. The current ROCE % is 19.51% and 178.9% above the Drug Manufacturers industry median of 7.00. Genomma Lab InternacionalB de CV's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (MEX:LABB), the current ROCE % is 19.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genomma Lab InternacionalB de CV (MEX:LABB) Overvalued in 2026?

Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued. The current stock price of MXN15.04 is trading 14.7% below its estimated GF Value™ of MXN17.64. GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.

Key valuation signals for MEX:LABB:

  • ROCE %: 19.51%
  • GF Value™: MXN17.64 vs. price of MXN15.04 (14.7% below fair value)
  • GF Score™: 66/100 with 4 warning signs
  • Industry Position: 178.9% above the Drug Manufacturers median

No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genomma Lab InternacionalB de CV Business Description

Other Exchanges GNMLF:USAGEKA:Germany
Address Avenida Antonio Dovali Jaime, Number 70, Tower C, Floor 2, Office A. Colonia Santa Fe, Del. Alvaro Obregon, Mexico, MEX, MEX, CP 01210
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
66GF Score

Get the complete analysis for MEX:LABB

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN15.04
Price
MXN17.64
GF Value